Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person8
Parabilis Medicines, Inc.
Company
Disc Medicine, Inc.
Company
Revolution Medicines, Inc.
Company
MEDICINOVA INC
Company
Editas Medicine, Inc.
Company
Clearmind Medicine Inc.
Company
Generate Biomedicines, Inc.
Company
Picard Medical, Inc.
Company
Primary record8
Parabilis Medicines, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On October 30, 2026, Parabilis Medicines, Inc. (the “Company”) and LS 400/500 CDP, LLC (the “Landlord”) entered into a Third Amendment of Lease (the “Amendment”), whi
MeiraGTx Holdings plc filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2026, the Board of Directors (the Board ) of
Parabilis Medicines, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. Parabilis Medicines, Inc. is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients
Parabilis Medicines, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) a
Parabilis Medicines, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 22, 2026, the Board of Directors (the “Board”) of Par
Parabilis Medicines, Inc. filed 4
SEC form 4 filed by Parabilis Medicines, Inc. (CIK 1657677) on 2026-08-25.
Parabilis Medicines, Inc. filed SCHEDULE 13G
on August 13, 2026. See row 5 of the cover pages. See row 6 of the cover pages. See row 7 of the cover pages. See row 8 of the cover pages. Y Y Y Y Y Y Exhibit 1 - Joint Filing Agreement ARCH Venture Fund XII, L.P. ARCH
Parabilis Medicines, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, Parabilis Medicines, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended June 30, 2026. A copy o